-
<![CDATA[CMS Announces 15 Drugs for Third Cycle of Medicare Drug Price Negotiation Program]]>
28 Jan 2026 20:05 GMT
… Medicare Drug … certolizumab pegol; UCB Pharma)
Cosentyx (secukinumab; Novartis)
Entyvio (vedolizumab; Takeda Pharmaceuticals … )
Erleada (apalutamide; Janssen Biotech) … medications such as Januvia (sitagliptin; Merck) for the treatment …
-
<![CDATA[Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations]]>
29 Jan 2026 03:12 GMT
…
Certolizumab pegol (Cimzia; UCB)
Secukinumab (Cosentyx; Novartis)
Vedolizumab (Entyvio; Takeda Pharmaceuticals) … and quality-of-life treatments, such as those … /medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation …
-
<![CDATA[CMS Announces 15 New High-Cost Drugs for Medicare Price Negotiation Program]]>
28 Jan 2026 17:39 GMT
… onabotulinumtoxinA (Botox and Botox Cosmetic), certolizumab pegol (Cimzia), secukinumab (Cosentyx), … -announces-selection-drugs-third-cycle-medicare-drug-price-negotiation-program … Lester M. What psoriasis treatments does Medicare cover? biologics and more …
-
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
28 Jan 2026 11:47 GMT
… drugs, expanding the scope of the program to include physician-administered treatments … and director of Medicare.
Drugs Selected for … (OTC:UCBJF) Cimzia (certolizumab pegol) for autoimmune diseases.
Novartis … breast cancer.
Takeda Pharmaceutical Company Ltd’s …
-
Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications
22 Jan 2026 16:54 GMT
… the use of conventional medications, treatment continuation, switching patterns, … by switching to vedolizumab, certolizumab pegol, golimumab, and ustekinumab … a prospective randomised trial. Gut. 2020;69 … data from clinical trials. Am J Gastroenterol …
-
From Methotrexate Resistance to Biologic and Targeted Pharmacotherapy: A Decade of Phase 4 Clinical Trials Evidence in Rheumatoid Arthritis
08 Jan 2026 14:03 GMT
… adalimumab, golimumab, and certolizumab pegol have consistently demonstrated efficacy … emergence of precision medicine approaches.12,13 … available results. Trials lacking defined treatment interventions or … in rheumatoid arthritis. Pharmaceuticals. 2023;16(3): …
-
Management and Treatment of Perianal Fistulizing Crohn’s Disease
12 Dec 2025 16:33 GMT
… and the medical system.11,13 Medical treatment includes …
Although randomized controlled trials specifically evaluating adalimumab … the Food and Drug Administration (FDA) for approval. … al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn …
-
New Crohn’s Guideline Stresses Early Use of Advanced Drugs
11 Dec 2025 10:43 GMT
… use of certolizumab pegol or vedolizumab over no treatment.
For … a lower-efficacy medication (vedolizumab or certolizumab pegol).
For adult … but prospective clinical trial data supporting this … said. Several ongoing clinical trials are assessing this endpoint …
-
Tumor Necrosis Factor Inhibitor Drugs Industry Analysis Report 2025: Key Trends, Drivers, and Forecast Insights
24 Nov 2025 00:00 GMT
… FDA approvals, a rise in disease incidence, clinical research and trials … inhibitor drugs are utilized in the treatment of … Pharmaceuticals, a company based in the US, collaborated with a biotechnology … By Cimzia: Cimzia (certolizumab pegol)
6) By Biosimilars: …
-
Inflammatory Bowel Disease Treatment Industry Analysis Report 2025: Key Trends, Drivers, and Forecast Insights
21 Nov 2025 05:22 GMT
… incorporation of precision medicine in IBD treatment. Major emerging … integrin, JAK inhibitors, Other Drug Classes
2) By Type … TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: … -market-report
Smart Pills Global Market Report …